May 22, 2023 8:05am EDT Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
May 18, 2023 8:00am EDT Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
Apr 28, 2023 8:15am EDT Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
Mar 30, 2023 4:01pm EDT Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
Mar 23, 2023 8:30am EDT Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
Mar 17, 2023 8:30am EDT Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
Mar 07, 2023 8:30am EST Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 21, 2023 8:30am EST Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
Feb 15, 2023 8:30am EST Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules
Feb 10, 2023 8:00am EST Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
